All companies
Visit website
AVACEN MEDICAL
OperatingAVACEN, Inc.
Healthcare · Founded 2017
Non-invasive, drug-free over-the-counter pain relief
Post-money valuation ⓘ
$76.2M
As of Oct 2023 · from AVACEN Medical Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$224,359
Across 1 round since 2023
Latest share price
$1.00
AVACEN Medical Common Stock 1 offering price
Financials
FY2021–FY2024 · from SEC filings · hover any figure for its source$4.6M
$45K
2021
$4.8M
$72K
2022
$5.3M
−$302K
2023
$4.3M
−$53K
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021
FY2022
FY2023
FY2024
Income statement
Revenue
$4,580,867
$4,793,309
$5,332,560
$4,332,532
Cost of goods sold
$1,948,778
$1,966,624
$2,656,093
$2,029,774
Gross margin
57%
59%
50%
53%
Net income
$45,430
$72,067
-$301,626
-$52,600
Taxes paid
$0
$0
$0
$0
Balance sheet
Cash
$1,309,009
$242,171
$157,964
$440,193
Accounts receivable
$8,950
$19,297
$106,282
$265,432
Total assets
$2,845,983
$2,242,798
$7,741,440
$8,674,313
Short-term debt
$645,389
$479,973
$496,332
$760,868
Long-term debt
$1,258,130
$1,788,703
$1,739,078
$2,392,463
Total liabilities
$1,903,519
$2,268,676
$2,235,410
$3,153,331
Other
Headcount
—
10
9
10
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$76.2M
post-money
AVACEN Medical Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $224.4K / $1.2MInvestors 194Post-money $76.2M
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 2 of 3 annual reports (FY2023–FY2025)
194 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 9 filings on EDGARSource: ManualCIK 0001472687Share price $1.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.